Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

PHAR Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Pharming Group N.V.NASDAQ: PHAR

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue dips below year-ago levels

Q1 FY2026 revenue of $72.45M fell 8.4% year over year, behind the +15.2% change in trailing-twelve-month revenue. Sequentially, it fell 31.9% from the prior quarter. Over 3 fiscal years it compounded at +22.4% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 3 analysts of $379.53M (+0.6%) for the fiscal year ending Dec 2026, a slowdown from the +22.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$72.45M-31.9% QoQ
Last fiscal yearDec 2025
$377.18M+22.6% YoY
LTMMar 2026
$369.38M+15.2% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.4%+6.8%+15.2 pp
1 year+22.6%+0.6%-21.9 pp
3-year CAGR+22.4%+2.1%-20.3 pp
5-year CAGR+11.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
377.18M USD
Year-over-year change
+22.6%
4-year CAGR
+13.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How PHAR compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +15.2% is the 4th highest of 7, against a peer median of +22.1%.
  • Over three fiscal years its annual growth of +22.4% compares with a peer median of +17.1%.
PHAR Competitors
Revenue for PHAR and competitors
Company Period LTM YoY 3-year CAGR
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$1.03T USD+33102.2%+15.4%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$959.76M USD-0.7%+17.1%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$940.61M USD+68.7%+47.8%
PHARPharming Group N.V.LTM Mar 2026$369.38M USD+15.2%+22.4%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$66.09M USD+45.0%+9.1%
STOKStoke Therapeutics, Inc.LTM Mar 2026$32.08M USD-83.2%+145.9%
PRQRProQR Therapeutics N.V.LTM Mar 2026€13.44M EUR-29.2%+62.0%
SLNSilence Therapeutics plcLTM Mar 2026$921.49K USD—-68.4%
PHVSPharvaris N.V.LTM Sep 2026€0 EUR——
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$0 USD——
Peer median (excluding PHAR) —+22.1%+17.1%

Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue225.46M205.62M245.32M307.75M377.18M
Cost of Revenue23.97M17.56M25.21M36.66M45.63M
Gross Profit201.49M188.06M220.1M271.09M331.56M
Gross Margin89.4%91.5%89.7%88.1%87.9%
Research & Development79.78M52.53M68.91M86.1M98.08M
Selling, General & Admin54.56M68.85M87.5M102.74M117.44M
Operating Expenses186.12M169.83M225.49M280.02M309.75M
Depreciation & Amortization22.23M13.19M15.93M16.64M10.76M
EBITDA55.3M33.53M9.88M16.89M31.7M
EBITDA Margin24.5%16.3%4.0%5.5%8.4%
Operating Income15.37M18.23M(5.39M)(8.93M)20.88M
Operating Margin6.8%8.9%-2.2%-2.9%5.5%
Interest Income59.99K85K3.53M5.92M2.56M
Interest Expense7M5.36M5.96M9.05M21.31M
Other Income / Expenses10.79M(3.25M)(6.63M)133.58K(8.03M)
Income Before Tax26.16M14.99M(12.01M)(8.79M)12.88M
Pre-Tax Margin11.6%7.3%-4.9%-2.9%3.4%
Income Tax Expense8.03M1.31M(1.46M)3.47M10.34M
Net Income18.13M13.67M(10.55M)(12.26M)2.86M
Net Margin8.0%6.7%-4.3%-4.0%0.8%
EPS (Basic)0.230.17(0.14)(0.18)0.04
EPS (Diluted)0.210.16(0.14)(0.18)0.04
Weighted Avg Shares87.64M82.54M65.7M68.92M71.32M
Weighted Avg Shares (Diluted)87.64M84.28M65.7M68.92M71.32M

Pharming Group N.V.

NASDAQ:PHAR

Intrinsic Alpha fair value

Locked

Current Price

$12.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.